Gabriel Nistor is the Chief Science Officer at AiVita Biomedical. He has over 20 years of experience in cancer immunology, stem cells, and cell biology. Previously, he held roles as Vice President of Research at Caladrius Biosciences and California Stem Cell, Inc., where he led teams in developing immunotherapies for cancer and stem cell therapies. He has a strong background in research and product development with a focus on quality and regulatory compliance.
Gabriel Nistor is the Chief Science Officer at AiVita Biomedical. He has over 20 years of experience in cancer immunology, stem cells, and cell biology. Previously, he held roles as Vice President of Research at Caladrius Biosciences and California Stem Cell, Inc., where he led teams in developing immunotherapies for cancer and stem cell therapies. He has a strong background in research and product development with a focus on quality and regulatory compliance.
Gabriel Nistor is the Chief Science Officer at AiVita Biomedical. He has over 20 years of experience in cancer immunology, stem cells, and cell biology. Previously, he held roles as Vice President of Research at Caladrius Biosciences and California Stem Cell, Inc., where he led teams in developing immunotherapies for cancer and stem cell therapies. He has a strong background in research and product development with a focus on quality and regulatory compliance.
Gabriel Nistor is the Chief Science Officer at AiVita Biomedical. He has over 20 years of experience in cancer immunology, stem cells, and cell biology. Previously, he held roles as Vice President of Research at Caladrius Biosciences and California Stem Cell, Inc., where he led teams in developing immunotherapies for cancer and stem cell therapies. He has a strong background in research and product development with a focus on quality and regulatory compliance.
Contact Gabriel Nistor www.linkedin.com/in/gabriel- Chief Science Officer, AiVita Biomedical nistor-5b637723 (LinkedIn) Orange County www.aivitabiomedical.com (Company) Summary Top Skills Broad, multidisciplinary knowledge and skills in all science areas, Cancer immunology with main expertise in biological and medical fields. My work is Stem Cells marked by scientific method, creativity, innovation, critical thinking, Cell Biology analysis, information synthesis and personal expression. I promote leadership by integrity, ethical judgment, personal example, clear Languages communication and skill transfer. I identify opportunities, translate to English (Native or Bilingual) business value and anticipate the challenges of complex scientific Romanian (Native or Bilingual) discoveries. Hungarian (Native or Bilingual)
Certifications Experience Amateur Radio License AIVITA Biomedical Inc Publications Chief Science Officer January 2016 - Present (5 years 3 months) Randomized phase II trial of Irvine, California autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional Caladrius Biosciences, Inc. analyses. Vice President, Research Derivation of oligodendrocyte May 2014 - January 2016 (1 year 9 months) progenitor cells from human Irvine, CA embryonic stem cells The most valued accomplishment is building my dedicated, highly skilled and Human Stem Cell-Derived Skin Progenitors Produce Alpha 2- versatile team capable of overcoming any given challenge. HS Glycoprotein (Fetuin): A Created a quality by design environment compliant with modern cGMP, to Revolutionary Cosmetic Ingredient. support the research, development and manufacturing troubleshooting in Histological and functional benefit following transplantation of motor phase III clinical trial for advanced stage melanoma using autologous tumor neuron progenitors to the injured rat initiating cells and autologous dendritic cells. spinal cord. Using patient samples, lead the investigation of the mechanism of action Cancer stem cell antigen-based in cancer immune-therapy. Developed final product potency assay and vaccines: the preferred strategy for active specific immunotherapy of discovered clinical predictive and efficacy biomarkers for dendritic cell based metastatic melanoma? immune-therapy that could complement the current approaches based on checkpoint inhibitors. Using complex investigative methods that included Patents exomic analysis of the purified tumor "stem" cells and mixed lymphocyte High purity ovarian cancer stem reactions elucidated multiple pathways of immune response to strong or weak cells for active autologous immune therapy Page 1 of 3
Bioreactor Cartridge and System antigens resulted from cancer associated mutations equally suggestive for Immunogenic compositions prepared immune-escape and tumorigenesis. from tumor cells derived from peripheral blood and originating from Investigated feasibility and established methods for manufacturing of purified a solid tumor and their use tumor stem cells as antigen sources for autologous immune-therapy approach Stem cell compositions for cosmetic in other types of cancer (hepatocellular carcinoma, ovarian cancer, non-small and dermatologic use lung cancer, glioblastoma etc). Neural cell purification for transplantation Successful isolated and expanded circulating tumor cells from cancer patients and identified factors that allow survival of the cells in routine blood samples. Developed proprietary reagents and methods that enabled consistent isolation of cancer "stem" cells from bulk tumors and rapid expansion for use as antigenic sources. Filed multiple patent applications and actively involved in developing company's IP portfolio strategy and in the patent prosecution process. Submitted and awarded multiple grants (CIRM, NIH) totaling over $20 millions.
California Stem Cell, Inc.
Vice President, Research and Development 2006 - 2014 (8 years) Adopted modern principles of product development based on quality by design: establishing critical quality attributes, process mapping, cause and effect analysis, design of experiments, risk assessment and management. Developed and patented reagent, manufacturing process, in-process control and releasing criteria for stem cell derivates suitable for cell-replacement therapies Coordinating the development of new pipelines of cell products with application in research and clinic. Participated in IND meetings for phase I for SMA stem cell therapy and for phase III Melanoma immunotherapy application Presented R&D pipeline and patent portfolio for investors in various fundraising occasions Developed methods for differentiating human embryonic stem cells in high purity populations of oligodendrocytes, neurons, cardiomyocytes, hepatocytes. Developed a concept and conditions for stemness maintenance, stem cell niche and differentiation mechanism of human embryonic stem cells, used successfully to grow very large quantities of cells with regulatory compliance. Developed in vitro human neuro-muscular system from stem cell derived motor neurons and primary myoblasts differentiated to skeletal muscle. Identified factors that are influencing the stem cell niche aging or renewal, that contribute to the maintenance of healthy organisms with applicability in immune-modulation, aging and cosmetics
Page 2 of 3
Transferred proof of concept immune-therapy technology from Hoag Hospital
to California Stem Cell Inc manufacturing. Improved manufacturing for purified tumor initiating cells with a new set of reagents and methods designed for high success rate. Developed patenting strategy for the manufacturing and final product applications in various cancers Actively participated with corporate legal office in pre-grant patent prosecution process for initial filings and multiple divisional and international filings.
University California Irvine
Postdoctoral Research January 2003 - 2006 (3 years)
County Hospital Tg.Mures
M.D. 1993 - 1999 (6 years)
Education University of California, Irvine Postdoctoral fellow, Neuroscience, Stem cells · (2003 - 2006)
University of Medicine and Pharmacy Tg Mures, Romania
Get The Case of the Frozen Addicts How the Solution of a Medical Mystery Revolutionized the Understanding of Parkinson s Disease 1st Edition J. W. Langston PDF ebook with Full Chapters Now
